DIWALI SPECIAL

25% OFF + 1-Yr NT Prime FREE !

Use
00h : 00m : 00s
Claim Offer →
logo
Market statusData NSENot investment advice
ANUH PHARMA

ANUH PHARMA Latest Share Price (ANUHPHR)

NSE: ANUHPHRBSE 506260HealthcarePharmaceuticalswww.anuhpharma.com
₹81.55
0.61−0.74%
Overall Score62/100
Day range81
₹81.55
84
52-week67
₹81.55
100
Above low+21.7%
Below high18.0%
Range position45%
Open83.92
Prev Close82.16
Bid81.52100
Ask81.58100

TODAY IN ONE LINE

ANUHPHR slipped 0.7% on light volume, lagging Nifty's 2.0% move.

With a market cap of ₹814.82 Cr., it trades at a P/E of N/A. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.

Volume59.5K−48%vs 20D avg
Price Band20
Lower Band63.1
Upper Band94.64
Tick Size0.01
Daily Volatility2.44%
Annualised Vol46.62%
Market Cap₹814.82 Cr.
Promoter71.78%
Face Value₹5
Fwd P/E—
PEG4.51
EV/EBITDA9.82
P/S1.06
ROA5.91%
Beta0.78
Div Payout36.59%
THE STOCK SCORE
Overall Score62/100
Updated 06 Nov

How good is this company?

Overall performance across 5 key dimensions.

Each card tappable → shows formula + inputs
FLAGS & NEWS

ANUH PHARMA flags & news 

Key strengths, potential risks, and recent updates.

✅ 5 green flags🚩 3 red flags

Green Flags

  • ●High Promoter HoldingPromoters hold 71.8% skin-in-the-game
  • ●Steady Dividend YieldReliable 1.85% dividend yield
  • ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
  • ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
  • ●Zero Pledge RiskNo recent active promoter pledging found

Red Flags

  • ●Earnings DeclineEPS (TTM) has contracted by 6.0% YoY
  • ●Sales ContractionQuarterly sales dropped 4.4% YoY
  • ●Rising Receivables vs SalesReceivables grew 17.1% outpacing sales growth of 2.2%

Latest ANUH PHARMA News

THE CHANGELOG

What changed recently?

Recent events, corporate actions, and announcements.

06 NOV 2026
corporate
Investor Presentation - Anuh Pharma Limited has informed the Exchange about Investor Presentation
View PDF
06 NOV 2026
corporate
Investor Presentation - Anuh Pharma Limited has informed the Exchange about Investor Presentation
View PDF
🔒Prime: full history + alerts on this stock
Valuation

ANUH PHARMA valuation: P/E, P/B and sector benchmarks.

Twelve years of multiples investors have paid for ANUH PHARMA, framed against the sector median so the premium or discount is obvious at a glance.

Key MetricsMarket + reported · 06 Nov 2026Consolidated

Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.

Valuation

Valuation

Market Cap
₹814.82 Cr.
P/E Ratio
—
P/B Ratio
—
EPS
₹1.12
Profitability

Profitability

ROE
11.65%
ROCE
11.96%
Net Margin
5.32%
Op Margin
7.09%
Growth

Growth

EPS YoY
-6%
Revenue YoY
2%
Qtr Sales
-4.42%
Qtr Profit
-1.85%
Financial Health

Financial Health

Debt / Equity
—
Book Value
₹35.14
Div Yield
1.85%
Promoter Holding
71.78%
Technicals

ANUH PHARMA technical analysis: indicators, pivots and CPR.

Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for ANUH PHARMA — derived from the latest tape, not yesterday's close.

ANUH PHARMA last traded at ₹81.55 with an intraday range of ₹81–₹83.94 — latest indicator, pivot and CPR signals below.

Last updated: 9 November 2026, 4:08 pm IST

Pivot points

Standard pivot — most widely referenced.

Pivot levels · Classic

Last: ₹81.55
LevelPrice (₹)Distance% Δ
R489.21+7.66+9.39%
R386.27+4.72+5.78%
R285.10+3.55+4.36%
R183.33+1.78+2.18%
PIVOT82.160.610.75%
CURRENT81.55——
S180.39-1.16-1.43%
S279.22-2.33-2.85%
S377.45-4.10-5.03%
S474.51-7.04-8.64%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: 81.86P: 82.16TC: 82.47
R1
R2
R3
R4
indicator
LTP: 81.55
PDH: 84.83
PDL: 81.15
● Market Sentiment

ANUHPHR is trading Below CPR, indicating Bearishness

● CPR Width

CPR is Wider, suggesting unlikely for trending moves

● Opening Range

Day's range: ₹82–₹83.94

● Price Position

Trading Inside opening range

Financials

ANUH PHARMA financials: P&L, balance sheet, cash flow, ratios.

Reported annual and quarterly results for ANUH PHARMA — consolidated or standalone — with margins, YoY growth and key ratios inline.

ANUH PHARMA reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹814.82 Cr. and reported EPS of ₹1.12.

iTap any row for a plain-English meaning▲▼Change vs a year ago — green means the move is healthy for that line, red means it isn’tDerivedCalculated by us, not reported directly
all values in ₹ Cr unless marked % / x / ₹ · fiscal-period end shown · reported figures via Stockezee financials API · annual results may be audited; quarterly results may be unaudited or limited-review
Segment Analysis

ANUH PHARMA segment analysis : revenue and profit mix.

Disclosed business segments at ANUH PHARMA with their share of revenue and profit, switchable between consolidated and standalone reporting.

ANUH PHARMA discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.

Segment-wise Financial Analysis

Thesis

The Bull, Bear, and Flip case for ANUH PHARMA.

Our AI distills the core fundamental drivers supporting ANUH PHARMA, the risks that threaten it, and the quantitative conditions that could weaken the thesis.

ANUH PHARMA's investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.

bull case

What you're getting.

No strengths or opportunities on record.

bear case

Key Risks.

  • SWOT generation temporarily unavailable due to model error. Bedrock invocation timeout

flip conditions

Flip Conditions.

  • Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.

  • Return-quality risk. ROE below 8% would indicate weaker capital compounding.

  • Income thesis breaks if the dividend is cut or yield falls below 0.93%.

Shareholding

ANUH PHARMA shareholding pattern: promoters, FII, DII and public.

Quarter-on-quarter ownership shifts in ANUH PHARMA — who is buying, who is exiting, and which institutions hold the largest positions.

Shareholding Pattern

Annual • Sep 2026

Promoters71.78%
Public28.09%↓0.10%
Promoter0.01%
FII0.11%↑0.10%

Ownership Distribution

Promoters
71.78%
Retail & Public
28.09%
Foreign Institutions
0.11%

Category Trends

Foreign Institutions Breakdown
Total Holding: 0.11%
Net Change: +0.10%
Category Total0.11%
Total Holding0.11%
Net Change+0.10%
Aggregate Data
Institution Name
Trend (Last 6)
Holding %
QoQ Change
YoY ChangePeriod

Foreign Institutions: 0.11%

Individual institutional breakdown is not disclosed by the company, but aggregate holding data is shown above.

💡 This category has 0.11% total holding without detailed institution-wise disclosure
Peers

ANUH PHARMA peer comparison — same-sector benchmarks.

Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — ANUH PHARMA is highlighted for quick read-across.

Quick Compare

Largest by Market Cap
MANIPAL HEALTH ENTERPRI L
₹85,012.83 Cr
Best Profit Growth
SHUKRA PHARMACEUTICALS L
742.72 %
Highest Dividend Yield
JENBURKT PHARMACEUTICAL L
2.20 %

Peer Comparison

Company Name
09 · Chart Patterns

ANUH PHARMA chart patterns: breakouts, tops and bottoms.

Auto-detected classical chart patterns for ANUH PHARMA — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.

Delivery Conviction

ANUH PHARMA delivery volume — last 20 sessions of conviction.

Daily traded volume and delivery percentage for ANUH PHARMA over 20 sessions — the gap between intraday flipping and genuine accumulation.

Latest session delivery in ANUH PHARMA stood at 55.1% of traded volume, against a 20-day average of 52.6%.

Avg Delivery (20D)52.6%+2.5 ppt latest vs avg
Highest Delivery67.5%on 21 Oct
Avg Volume (20D)1.14 L20-day run-rate
Conviction Trend↓ Weakening+2.5 ppt latest read
Volume & Delivery · last 20 sessions
Exchange Filings & Investor Updates

ANUH PHARMA announcements: results, concalls, ratings, M&A.

Filings ANUH PHARMA sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.

ANUH PHARMA files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 89 documents below.

  1. 06 Nov 2026Investor PresentationView PDF

    Investor Presentation

    Anuh Pharma Limited has informed the Exchange about Investor Presentation

  2. 01 Nov 2026Copy of Newspaper PublicationView PDF

    Copy of Newspaper Publication

    Anuh Pharma Limited has informed the Exchange about Copy of Newspaper Publication of the Unaudited Financial Results for the Quarter and half year…

  3. 30 Oct 2026UpdatesView PDF

    Updates

    Anuh Pharma Limited has informed the Exchange regarding 'Request received for Withdrawal of application for reclassification of shareholding from…

  4. 30 Oct 2026UpdatesView PDF

    Updates

    Anuh Pharma Limited has informed the Exchange regarding 'Financial Results'.

  5. 30 Oct 2026Outcome of Board MeetingView PDF

    Outcome of Board Meeting

    Anuh Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

Corporate Actions

ANUH PHARMA dividend history, splits and bonus issues.

Every dividend, stock split and bonus issue ANUH PHARMA has declared, sequenced by announce and record date.

ANUH PHARMA corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.

About the Company

About ANUH PHARMA: business, sector, key facts.

What ANUH PHARMA does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.

ANUH PHARMA operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: ANUHPHR, BSE: 506260.

ANUHPHR
Healthcare

ANUH PHARMA

NSE · ANUHPHR·BSE · 506260·www.anuhpharma.com

Anuh Pharma Limited is an Indian pharmaceutical company primarily focused on the manufacturing and sale of bulk drugs and chemicals. Its core business revolves around the production of Active Pharmaceutical Ingredients (APIs), which are the fundamental components used in the formulation of various medicines. This makes Anuh Pharma a key player in the pharmaceutical supply chain, rather than directly selling finished medications to consumers.

The company's API portfolio is quite diverse, encompassing a wide range of therapeutic areas. Key product categories include macrolides (a class of antibiotics), anti-tuberculosis drugs, anti-malarial medications, and various antibacterial agents. Beyond infectious disease treatments, Anuh Pharma also produces APIs for cardiovascular health (anti-hypertension drugs) and respiratory conditions (expectorants). Further broadening their product line, they offer quinolones (another class of antibiotics) and essential intermediates used in the synthesis of other APIs. This demonstrates a strategic approach to supplying raw materials for a significant portion of the pharmaceutical market.

In addition to its extensive range of antibiotics and cardiovascular APIs, Anuh Pharma also manufactures corticosteroids. These versatile drugs have a variety of applications, including anti-inflammatory, immunosuppressant, anti-pruritic (anti-itch), anti-mitotic (cell division inhibiting), and anti-histamine properties. This further diversifies their product offering and caters to a broader range of pharmaceutical needs. The production of corticosteroids showcases Anuh Pharma's capability in complex chemical synthesis and manufacturing processes.

An important aspect of Anuh Pharma's business model is its export operations. The company actively engages in international trade, selling its APIs to pharmaceutical companies and manufacturers in various countries. This signifies a significant presence in the global pharmaceutical supply chain and contributes to the company's revenue generation. The international market access enhances its reach and potential for growth.

Established in 1960 and headquartered in Mumbai, Anuh Pharma has a long history of operation within the Indian pharmaceutical industry. Its longevity and consistent production of a broad array of APIs illustrate a commitment to quality and sustained relevance in a competitive market. The company’s continued success likely hinges on its ability to adapt to evolving market demands and technological advancements in pharmaceutical manufacturing.

company facts
Employees—
SectorHealthcare
HeadquartersMumbai, India
Market Cap₹814.82 Cr.
Listed OnNSE
leadership25 on record
Dr. Mita Dixit
Additional Non-Executive Independent Woman Director
Mr. Amit R. Saratkar
Assistant General Manager of HR Strategy and Transformation
Mr. Arun Todarwal
Non-Executive Chairman of the Board
Mr. Babu K. Moghaveera
Assistant General Manager of Technical
Mr. Bijal Kaushal H. Shroff
Regional Head of India, SAARC & MENA
Mr. Bipin Nemchand Shah
Non-Executive Director
Mr. Bipin Nemchand Shah
Non-Executive Vice Chairman of the Board
Mr. Darshan Dhirajlal Rampariya
Chief Financial Officer
Mr. Darshan Rampariya
Chief Financial Officer
Mr. Gaurav Shah
Additional Non-Executive Director
Mr. Harmanbhai Patel
Non-Executive Independent Director
Mr. Ketan Shah
Non-Executive Director
§ ∞ · Plainly Answered

Questions investors ask about ANUH PHARMA (ANUHPHR).

Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.

01What is the current share price of ANUH PHARMA (ANUHPHR)?

The current share price of ANUH PHARMA (ANUHPHR) is ₹81.55. Today, the stock has declined by ₹0.61 (0.74%), trading in a range of ₹81.00 to ₹83.94. The stock opened at ₹83.92 with a trading volume of 59,502 shares.

02Is ANUH PHARMA stock a good investment for long-term?

ANUH PHARMA can be considered for long-term investment based on several factors. The company has a market capitalization of ₹814.82 Cr., P/E ratio of 0, ROE of 11.65%, and ROCE of 11.96%. The dividend yield stands at 1.85%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.

03What is the 52-week high and low price of ANUH PHARMA stock?

The 52-week high price of ANUH PHARMA (ANUHPHR) is ₹99.50, while the 52-week low is ₹67.00. Currently trading at ₹81.55, the stock is 21.72% above its 52-week low and 18.04% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.

04Should I buy ANUH PHARMA stock at the current price?

Whether to buy ANUH PHARMA stock at ₹81.55 depends on multiple factors. The stock is currently trading with a P/E ratio of 0 and P/B ratio of 0. Today's performance shows a loss of 0.74%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.

05What is the dividend yield of ANUH PHARMA and when is the next dividend?

ANUH PHARMA offers a dividend yield of 1.85%, which means for every ₹100 invested at the current price of ₹81.55, you can expect to receive approximately ₹1.85 annually as dividends. The face value of the stock is ₹5.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.

06What are the key financial ratios and metrics of ANUH PHARMA?

ANUH PHARMA's key financial metrics include: P/E Ratio: 0, P/B Ratio: 0, ROE: 11.65%, ROCE: 11.96%, Dividend Yield: 1.85%, EPS: ₹1.12, Book Value: ₹35.14, and Debt-to-Equity: 0. The company's market cap stands at ₹814.82 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.

07How is ANUH PHARMA stock performing today in the market?

ANUH PHARMA stock opened at ₹83.92 and is currently trading at ₹81.55, showing a decline of ₹0.61 (0.74%). The intraday high is ₹83.94 and low is ₹81.00. The trading volume stands at 59,502 shares, indicating moderate market participation today.

08What is the P/E ratio of ANUH PHARMA and what does it indicate?

ANUH PHARMA has a Price-to-Earnings (P/E) ratio of 0, which means investors are willing to pay 0.00 for every ₹1 of earnings. With an EPS of ₹1.12, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.

Disclaimer

The data, ratios and commentary about ANUH PHARMA (ANUHPHR) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.